As a second-line treatment, osimertinb significantly prolonged the progression-free survival (PFS) of metastatic EGFR-mutant NSCLC patients who acquired the EGFR T790M mutation to 8.5 months compared to those receiving platinum therapy plus pemetrexed (PFS = 4.2 months) [53]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.